Navigation Links
Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced encouraging results from the analysis of overall survival (OS) time for patients in the Company's double-blind, randomized, controlled, multi-center Phase 2b clinical trial in metastatic melanoma for its lead compound, STA-4783.

The analysis of overall survival showed that patients randomized to receive STA-4783 plus paclitaxel (N=53) experienced a median survival of 12 months, compared to 7.8 months for all patients who initially received paclitaxel alone (N=28). The Phase 2b trial included a crossover design that allowed patients who initially received paclitaxel alone to receive STA-4783 plus paclitaxel following evidence of a worsening of their disease. Of the 28 patients who initially received paclitaxel alone, 19 elected to subsequently receive STA-4783. The median overall survival for this group was 14.3 months. By contrast, the group of patients initially treated with paclitaxel alone who did not subsequently receive STA-4783 experienced a median survival of 5.6 months. Other randomized trial results in metastatic melanoma have consistently shown a median survival time of between six and nine months regardless of treatment (1).

"The new overall survival results reinforce the previously-reported positive results from this trial, including meeting the primary endpoint of progression free survival (PFS) and showing substantial improvement in tumor response rate," said Safi Bahcall, Ph.D., President and Chief Executive Officer of Synta. "The collective results on the anti-cancer activity of STA-4783 in metastatic melanoma, together with the favorable safety profile, are very encouraging and suggest that this novel mechanism compound has potential as an im
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Synta Pharmaceuticals to Host Conference Call Today
2. Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:5/22/2013)... TORONTO , May 22, 2013 /PRNewswire/ ... announced three presentations demonstrating the superiority of the AE37 ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations will ... Society of Clinical Oncology (ASCO) to be held in ... June 4, 2013. The presentation entitled " ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... 48-week investigational regimen yielded nearly double SVR rate ... protease inhibitor SCH 900518 presented at EASL annual ... SGP ) today reported that final ... its investigational oral hepatitis C protease inhibitor, in ...
... Potential of Fully Human Anti-PS Antibodies and ... Equivalent to the Human Antibody Inhibited Tumor ... More than 90%-DENVER and TUSTIN, Calif., April ... PPHM), a clinical stage biopharmaceutical company ...
Cached Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 2Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 3Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 4
(Date:5/22/2013)... ID (PRWEB) May 22, 2013 Bodybuilding.com ... This Memorial Day (May 27, 2013) Bodybuilding.com will be donating ... of the amount. , “We are extremely grateful for ... the Armed Forces,” said Ryan DeLuca, CEO and founder of ... heroes who have sacrificed so much. Hire Heroes USA is ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Today, Zane ... Alabama Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution plans ... to Zane Benefits’ website, beginning in 2014 as part ... for individuals and small businesses will become available through ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) ... deal of suffering, but new research indicates the combination ... entirely -- a smaller brain. , , Already aware ... depression, scientists wanted to determine if having both conditions ... -- about 2 percent -- isn,t alarming, study authors ...
(Date:5/22/2013)... Recent tragedies including the Oklahoma ... shooting in Newtown, Connecticut all resulted in serious, ... Emergency medical practitioners train to respond to both ... Services for Children (EMSC) Program specifically provides instruction, ... youngest patients. It is estimated 30 million children ...
(Date:5/22/2013)... loving child care is one of the most important things ... in their search, Paty’s Daycare has launched a new ... and much more. , “Our new website is vibrant, fun ... “Auntie Paty” Sutton, founder of Paty’s Daycare. “Just as you ... the first time that you walk through the front door ...
Breaking Medicine News(10 mins):Health News:In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:Paty’s Daycare Launches New Website to Connect with Parents in Need of Nurturing Child Care 2
... The largest single-institution study of its kind has found ... after surgery to remove the prostate. Men in this ... following surgery indicated their cancer had recurred. ... in Florida and Minnesota suggest that patients and their ...
... procedure extends survival of cancer patients, , MONDAY, Sept. 28 ... a healthy breast removed after being diagnosed with breast cancer ... that this practice is actually beneficial in terms of improving ... in Cancer . , The researchers, led by ...
... UofT researchers have used nanomaterials to develop a ... severity of a patient,s cancer so that the disease ... Their groundbreaking work, reported Sept. 27 in Nature ... will become commonplace. "This remarkable innovation is an ...
... University School of Medicine (BUSM) are recommending that menopausal ... to having their annual mammogram screenings. These recommendations appear ... Journal of the North American Menopause Society . ... reduction in breast cancer mortality in women older than ...
... ... Research , ... September 28, 2009 -- Axiom Accelerated Patient Recruitment (Axiom), one of the ... messaging (SMS) services. , , , , ,"Mobile device outreach is the future of ...
... At ... Hell Doctors will join with their supporters in Washington D.C.,s Lafayette Park. , ... Washington, DC (PRWEB) September 28, 2009 --, ... single-payer advocacy tour, the Mad As Hell Doctors from Portland, Oregon will hold ...
Cached Medicine News:Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 2Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 3Health News:More Women Having Other Breast Removed 2Health News:More Women Having Other Breast Removed 3Health News:U of T researchers create microchip that can detect type and severity of cancer 2Health News:Researchers believe hormone therapy should not be stopped prior to mammograms 2Health News:Axiom Accelerated Patient Recruitment Rolls Out 2Health News:Mad As Hell Doctors to Hold Final "White Ribbon Rally" for Single Payer in Washington, D.C. on September 30th 2Health News:Mad As Hell Doctors to Hold Final "White Ribbon Rally" for Single Payer in Washington, D.C. on September 30th 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: